Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Apatinib

Chlorotrianisene

Protein Kinase Inhibitors

Enzyme Inhibitors

Estrogens

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib).

TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.

TACE+Camrelizumab+Apatinib mesylate

TACE

Linna Wang

Hejuan Song

Jia Fan

A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.

This is a Randomized, Open-Label, Multi-center phase III clinical trial。

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

A Phase III, Randomized, Open-Label, Multi-center Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) or TACE Alone in Patients With Incurable Hepatocellular Carcinoma

PFS is defined as the time from the date of randomization until the date of first objective disease progression or death (whichever occurs first).

OS is defined as the time from the date of randomization until death due to any cause.

ORR is defined as the percentage of participants in the analysis population who have a CR or PR.

DCR is defined as the percentage of participants in the analysis population who have a CR, PR or SD.

DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma	NCT05320692	Hepatocellular ...	TACE+Camrelizum... TACE	18 Years -	Jiangsu HengRui Medicine Co., Ltd.
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma	NCT05320692	Hepatocellular ...	TACE+Camrelizum... TACE	18 Years -	Jiangsu HengRui Medicine Co., Ltd.

Spots Global Cancer Trial Database for tace+camrelizumab+apatinib mesylate